Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity
Open Access
- 1 October 2021
- journal article
- review article
- Published by Pulmonary Hypertension Association in Advances in Pulmonary Hypertension
- Vol. 20 (4) , 109-118
Abstract
Connective tissue diseases are a multisystem disorder that can cause impairments in quality of life, shorten life expectancy, and increase the risk of mortality at a younger age. These patients have an increased risk for the development of pulmonary hypertension through several mechanisms including pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. This review aims to discuss the various presentations of connective tissue disease associated with pulmonary hypertension associated with interstitial lung disease, demographics, and survival. It gives an overview of accepted mechanisms of disease pathogenesis, discusses advances in diagnostics, and treatment options. Despite a deeper understanding of disease pathogenesis, treatment for this remains limited to prevention of disease progression. The identification of the primary disease driver requires careful evaluation of the disease phenotype and is a potential target for treatment and prevention of death.Keywords
This publication has 56 references indexed in Scilit:
- The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung DiseaseChest, 2020
- Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung DiseaseArthritis & Rheumatology, 2020
- A Randomized, Double-Blind, Placebo-Controlled Study of Pulsed, Inhaled Nitric Oxide in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary FibrosisChest, 2020
- Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA StudyLung, 2017
- Borderline Mean Pulmonary Artery Pressure in Patients With Systemic Sclerosis: Transpulmonary Gradient Predicts Risk of Developing Pulmonary HypertensionArthritis & Rheumatism, 2012
- Randomized, prospective, placebo‐controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosisArthritis & Rheumatism, 2010
- Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung diseaseArthritis & Rheumatism, 2009
- The distance-saturation product predicts mortality in idiopathic pulmonary fibrosisRespiratory Medicine, 2006
- Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trialThe Lancet, 2002
- Isolated diffusing capacity reduction in systemic sclerosisArthritis & Rheumatism, 1992